Anthem Biosciences Q3 FY26 earnings call

Mon 9 Feb 2026ANTHEM

In brief

The recording, the transcript and our read of the call usually follow within a few days. Nothing beyond the invite is filed yet.

The numbers

The quarter, Q3 FY26

This quarterA year agoLast quarterMargin
Revenue₹423 cr—−23.1%
EBITDA (excl. other income)₹132 cr—−39.5%31.2%
Net profit₹0 cr——0%
EPS (₹)₹1.65—−46.6%

From the company's filed results for the quarter ended 31 Dec 2025 (consolidated), not from the call. EBITDA here excludes other income, so it can differ from the figure management quotes.

Guidance

Guided on earlier calls, and what was filed

WhatForGuidedFiled
EBITDA marginFY26at least 38% (on the Q1 FY26 call)38.1%, within the range
EBITDA margin (normalized, excl FX)FY2636–37% (on the Q2 FY26 call)38.1%, above the range

Filed figures are summed from the company's own quarterly results for the whole period (EBITDA excludes other income); where one sits against what was guided is arithmetic, not a judgement.

Transcript

We have not transcribed this call's recording. Read the company's transcript (PDF).

The stock after the call

After the callCloseStockNifty 50
Next session Mon 9 Feb 2026₹674.90+3.37%+0.68%
5 sessions Fri 13 Feb 2026₹689.95+5.67%−0.87%
20 sessions Mon 9 Mar 2026₹660.15+1.11%−6.48%

From the close of Fri 6 Feb 2026, ₹652.90: the close before the call day (the call's time is not on file). Adjusted daily closes; the move includes everything else that happened in those sessions.

Anthem Biosciences's other calls

  • Q2 FY27Wed 4 Nov 2026Tone: Confident
  • Q1 FY27Wed 22 Jul 2026Tone: Confident
  • Q4 FY26Wed 20 May 2026Tone: Confident
  • Q3 FY26Thu 5 Feb 2026Not read
  • Q2 FY26Mon 10 Nov 2025Tone: Confident
  • Q1 FY26Thu 14 Aug 2025Tone: Confident